BioCardia (BCDA) Projected to Announce Earnings on Wednesday

BioCardia (NASDAQ:BCDA) is projected to announce its Q3 2026 resultson Wednesday, November 11th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 4:30 PM ET.

BioCardia (NASDAQ:BCDA) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.05. On average, analysts expect BioCardia to post ($0.71) EPS for the current fiscal year and ($0.58) EPS for the next fiscal year.

BioCardia Stock Up 2.2%

Shares of NASDAQ BCDA opened at $0.92 on Wednesday. The firm has a market cap of $13.95 million, a P/E ratio of -1.44 and a beta of 0.69. The company has a 50 day moving average of $1.04 and a 200 day moving average of $1.07. BioCardia has a twelve month low of $0.75 and a twelve month high of $1.80.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of BioCardia in a report on Thursday, October 15th. HC Wainwright reissued a “buy” rating on shares of BioCardia in a research note on Monday, August 24th. Wall Street Zen raised shares of BioCardia from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Finally, Zacks Research raised shares of BioCardia from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 11th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, BioCardia has a consensus rating of “Hold” and an average price target of $25.00.

BioCardia Company Profile

BioCardia, Inc is a biotechnology company focused on developing regenerative cell therapies and delivery systems for the treatment of cardiovascular diseases. The company’s programs are designed to address conditions in which damaged or poorly functioning heart tissue may benefit from cellular therapy.

BioCardia’s principal product candidates include CardiAMP Cell Therapy, an autologous treatment that uses a patient’s own bone marrow-derived cells, and CardiALLO Cell Therapy, an investigational allogeneic therapy based on mesenchymal precursor cells from a donor source.